// App-Quantinova.ai

269 : Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).

Researchers

Presenter

  • Robert J. Motzer

Principal Investigators

  • Masatoshi Eto

  • Thomas Powles

  • Viktor Grnwald

  • Thomas E. Hutson

  • Boris Alekseev

  • Sun Young Rha

  • Evgeny Kopyltsov

  • Mara Jos Mndez Vidal

  • Sung-Hoo Hong

  • Anil Kapoor

  • Teresa Alonso Gordoa

  • Jeffrey C. Goh

  • Jaime R. Merchan

  • Alan D. Smith

  • Kalgi Mody

  • Rodolfo F. Perini

  • Dongyuan Xing

  • Toni K. Choueiri

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • IRCCS San Matteo University Hospital Foundation, Padua, Italy

  • Kyushu University, Fukuoka, Japan

  • The Royal Free NHS Trust, London, United Kingdom

  • University Hospital of Essen, Essen, Germany

  • Texas Oncology, Dallas, TX

  • P.A. Herzen Moscow Cancer Research Institute, Moscow, Russia

  • Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea

  • State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russian Federation

  • Maimonides Institute for Biomedical research of Cordoba (IMIBIC) Hospital Universitario Reina Sofía, Córdoba, Spain

  • Pediatrics, Seoul National University Bundang Hospital, Gyeonggi-do, Korea

  • McMaster University, Hamilton, ON, Canada

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • ICON Research, South Brisbane & University of Queensland, St Lucia, QLD, Australia

  • University of Miami/Sylvester Cancer Center, Miami, FL

  • Eisai Ltd., Hatfield, United Kingdom

  • Eisai Inc, Woodcliff Lake, NJ

  • Merck & Co., Inc., Kenilworth, NJ

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Italy

  • Japan

  • United Kingdom

  • Germany

  • Russia

  • Republic of South Korea

  • Spain

  • Canada

  • Australia

Companies

  • Eisai Inc.

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Pembrolizumab

  • Everolimus

  • Lenvatinib

  • Sunitinib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02811861

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved